Rare diseases
Investigational molecules
Locations
293 conditions with trials, the busiest first
1 664 trials across Europe, recruiting first
Safety and Tolerability of Benralizumab in Patients with HES, EGPA, or Asthma Who Completed a Prior Study
AustriaStudy of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis
CroatiaPhase 2 Study of Nemolizumab for Skin Thickening in Adults with Systemic Sclerosis
BulgariaLong‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis
AustriaA Phase 2a Study of ly4005130 in Adults with Severe Alopecia Areata
The NetherlandsEvaluation of Anifrolumab Subcutaneous Treatment in Immunosuppressant‑Naïve and Biologic‑Naïve Patients with Systemic Lupus Erythematosus
FranceEfficacy and Safety of LY4005130 Compared with Placebo in Adults with Non‑Segmental Vitiligo
BelgiumLong-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis
BelgiumBI 3000202 in Patients with Moderate to Severe Systemic Lupus Erythematosus
BulgariaA study to evaluate the effectiveness of barzolvolimab in participants with cold urticaria and symptomatic dermographism
GermanyA study to evaluate the effectiveness and safety of LAD603 in adults with severe to very severe alopecia areata
BulgariaA study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria
BelgiumThe therapies tested most often in Immune system disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
